Publication of the annual report and invitation to the ordinary and extraordinary shareholders’ meetings
March 27 2020 - 4:01PM
Publication of the annual report and invitation to the ordinary and
extraordinary shareholders’ meetings
Mechelen, Belgium; 27 March 2020, 21.15 CET; regulated
information – Galapagos NV (Euronext & NASDAQ: GLPG) published
its annual report for the financial year 2019.
The annual report for the financial year 2019,
including a review of figures and performance, is available online
at https://www.glpg.com/financial-reports and can also be
downloaded as PDF. Our annual 2019 Form 20-F filing with the SEC is
also available at www.sec.gov/edgar.
Furthermore, Galapagos has the honor to invite its shareholders,
holders of subscription rights, directors, and statutory auditor to
its annual (ordinary) and extraordinary shareholders’ meetings that
will be held on Tuesday 28 April 2020 at 2:00 p.m. (CET) at the
Company’s registered office. The items on the
agenda of the ordinary and extraordinary shareholders’ meetings
include, amongst other items, the appointment of Dr. Elisabeth
Svanberg as an independent director, the amendment of the Company’s
corporate purpose, and the amendment of the articles of association
to implement several provisions of the new Belgian Companies Code.
Elisabeth Svanberg received her MD and PhD from the University
of Gothenburg, Sweden, and is a board certified general surgeon and
associate professor of surgery. She joined Serono International in
2000, initially in the field of metabolism and subsequently held
roles of increasing responsibilities before joining Bristol Myers
Squibb (BMS) in the United States in 2007. At BMS, Elisabeth served
as development leader for a first in class novel diabetes medicine
and subsequently as Head of Medical Affairs for the
Intercontinental region. In 2014, Elisabeth joined Janssen
Pharmaceuticals (a Johnson & Johnson Company) as Vice
President, Head of the Established Products group, managing a
portfolio of 90 products used by an estimated 150 million patients
globally. Since 2016, Elisabeth serves as Chief Development Officer
at Ixaltis SA, a specialty pharmaceutical company developing
proprietary therapeutics to treat genitourinary (GU) disorders with
unmet medical need. Elisabeth serves as a non-executive director on
the board of PledPharma (since 2017) and Swedish Orphan Biovitrum
(SOBI, since 2018).
In order to be admitted to the shareholders’ meetings, the
holders of securities issued by the Company must comply with
article 7:134 of the Belgian Code of Companies and
Associations and article 29 of the Company’s articles of
association, and fulfill the formalities described in the convening
notice. The convening notice and other documents pertaining to the
shareholders’ meetings, including the biography of Dr. Svanberg,
can be consulted on our website,
www.glpg.com/shareholders-meetings.
In observance of the coronavirus (COVID-19) pandemic, Galapagos
strongly encourages its shareholders not to attend the meetings in
person, but to vote remotely, prior to the meetings, or to exercise
your voting right through a written proxy. Please see the convening
notice for more details on how to exercise your voting right.
We actively monitor the public health and travel safety
concerns relating to the coronavirus, and the advisories or
mandates that federal, regional and local governments, and related
agencies, may issue. We can only allow access to shareholders,
proxyholders and other persons at the shareholders’ meetings to the
extent permitted under the measures taken by the Belgian
authorities as applicable at the time of the meetings. In the event
that it is not possible or advisable to hold the shareholders’
meetings as currently planned, we will publicly announce any
additional or alternative arrangements for the meetings and we will
update our meeting page at the Galapagos website:
https://www.glpg.com/shareholders-meetings, which we encourage you
to monitor for the most recent information.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops
small molecule medicines with novel modes of action, three of which
show promising patient results and are currently in late-stage
development in multiple diseases. Our pipeline comprises discovery
through Phase 3 programs in inflammation, fibrosis, osteoarthritis
and other indications. Our ambition is to become a leading global
biopharmaceutical company focused on the discovery, development and
commercialization of innovative medicines. More information at
www.glpg.com.
Contact
Investors:
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784
Sofie Van Gijsel
Director Investor Relations
+32 485 19 14 15
ir@glpg.com
Media:
Carmen Vroonen
Senior Director Communications & Public Affairs
+32 473 824 874
Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com
Forward-looking statements
This release may contain forward-looking statements. Such
forward-looking statements are not guarantees of future results.
These forward-looking statements speak only as of the date of
publication of this document. Galapagos expressly disclaims any
obligation to update any forward-looking statements in this
document, unless specifically required by law or regulation.
Disclaimer
The contents of our website, including the annual report
for the financial year 2019, and any other website that may be
accessed from our website, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024